Journal ArticleDOI
Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial
Reads0
Chats0
TLDR
Locally injected eASCs appear to be a simple, safe, and beneficial therapy for perianal fistula in Crohn’s disease patients, and additional studies are needed to further confirm the efficacy of the eASC.Abstract:
Purpose
The management of perianal fistula in patients with Crohn’s disease is an extremely challenging medical problem as many fistulas do not respond to available treatments The objectives were to assess the safety and efficacy of a suspension of expanded adipose-derived allogeneic mesenchymal stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s diseaseread more
Citations
More filters
Journal ArticleDOI
Surgical management of complex perianal fistula revisited in a systematic review: a critical view of available scientific evidence
TL;DR: In this paper , the authors performed a systematic literature review to compare the results of these different techniques in the treatment of Crohn's or Cryptoglandular fistula treatment, which have different etiology, and this might interfere with its effectiveness, in addition they increase fecal incontinence risk.
Journal ArticleDOI
A Phase IB/IIA study of allogeneic bone marrow derived mesenchymal stem cells for the treatment of refractory ileal anal anastomosis and peripouch fistulas in the setting of Crohn's disease of the pouch.
Amy L. Lightner,Jane S. Reese,Justin R. Ream,Douglas Nachand,X Jia,Ana M. Otero Piñeiro,Neda Dadgar,Scott J. Steele,Tracy L. Hull +8 more
TL;DR: In this article , a phase IB/IIA randomized control trial of bone marrow derived allogeneic MSCs via direct injection to treat adult patients with a peripouch fistula(s) was conducted.
Book ChapterDOI
Advances in Colorectal Surgery
TL;DR: The need to reduce the variability of clinical practice in rectal cancer surgery, the controversy generated by their approach, and its relation with pelvic floor muscles and anal canal sphincter have increase the interest in local surgery and minimally invasive procedures.
Journal ArticleDOI
Surgical treatment of perianal fistula in Crohn's disease
TL;DR: Ligation of intersphincteric fistula and autologous or allogenic stem cells are new surgical procedures for treatment of Crohn’s disease that need further studies.
Journal ArticleDOI
Clinical Research Progress of Crohn
TL;DR: This paper summarizes the application and efficacy of related therapies in CD, providing a reference for clinicians and showing that Mesenchymal Stem Cells (MSC) can down-regulate immune response and promote tissue healing has certain safety and effectiveness.
References
More filters
Journal ArticleDOI
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
Massimo Di Nicola,Carmelo Carlo-Stella,Michele Magni,Marco Milanesi,Paolo Longoni,Paola Matteucci,Salvatore Grisanti,Alessandro M. Gianni +7 more
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Human mesenchymal stem cells modulate B-cell functions
Anna Corcione,Federica Benvenuto,Elisa Ferretti,Debora Giunti,Valentina Cappiello,Francesco Cazzanti,Marco Risso,Francesca Gualandi,Giovanni Luigi Mancardi,Vito Pistoia,Antonio Uccelli +10 more
TL;DR: The results further support the potential therapeutic use of hMSCs in immune-mediated disorders, including those in which B cells play a major role.
Journal ArticleDOI
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Journal ArticleDOI
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
Mauro Krampera,Sarah Glennie,Julian Dyson,Diane Scott,R. Laylor,Elizabeth Simpson,Francesco Dazzi +6 more
TL;DR: It is suggested that MSCs physically hinder T cells from the contact with APCs in a noncognate fashion and inhibit naive and memory T-cell responses to their cognate antigens.